James W Hodge

Scopus Author ID ResearcherID ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 30

Top Topics

Squamous Cell Carcinoma

Histone Deacetylase

Top Venues

Journal for immunotherapy of cancer

Cancer biology & therapy

Clinical cancer research : an official journal of the American Association for Cancer Research

This page only lists publications with an associated author ORCID identifier.

Publications

Jeffrey Schlom, Renee N Donahue, Claudia Palena, Sofia R Gameiro, James W Hodge, Duane H Hamilton, James L Gulley
Hypothesis: the generation of T cells directed against neoepitopes employing immune-mediating agents other than neoepitope vaccines. Journal for immunotherapy of cancer 12 (7) (2024)
Jeffrey Schlom, Renee N Donahue, Claudia Palena, Sofia R Gameiro, James W Hodge, Duane H Hamilton, James L Gulley
Hypothesis: the generation of T cells directed against neoepitopes employing immune-mediating agents other than neoepitope vaccines. Journal for immunotherapy of cancer 12 (7) (2024)
Jeffrey Schlom, Renee N Donahue, Claudia Palena, Sofia R Gameiro, James W Hodge, Duane H Hamilton, James L Gulley
Hypothesis: the generation of T cells directed against neoepitopes employing immune-mediating agents other than neoepitope vaccines. Journal for immunotherapy of cancer 12 (7) (2024)
Jeffrey Schlom, Renee N Donahue, Claudia Palena, Sofia R Gameiro, James W Hodge, Duane H Hamilton, James L Gulley
Hypothesis: the generation of T cells directed against neoepitopes employing immune-mediating agents other than neoepitope vaccines. Journal for immunotherapy of cancer 12 (7) (2024)
Ginette S Santiago-Sanchez, Kellsye P Fabian, James W Hodge
A landscape of checkpoint blockade resistance in cancer: underlying mechanisms and current strategies to overcome resistance. Cancer biology & therapy 25 (1) (2024)
Ginette S Santiago-Sanchez, Kellsye P Fabian, James W Hodge
A landscape of checkpoint blockade resistance in cancer: underlying mechanisms and current strategies to overcome resistance. Cancer biology & therapy 25 (1) (2024)
Ginette S Santiago-Sanchez, Kellsye P Fabian, James W Hodge
A landscape of checkpoint blockade resistance in cancer: underlying mechanisms and current strategies to overcome resistance. Cancer biology & therapy 25 (1) (2024)
Ginette S Santiago-Sanchez, Kellsye P Fabian, James W Hodge
A landscape of checkpoint blockade resistance in cancer: underlying mechanisms and current strategies to overcome resistance. Cancer biology & therapy 25 (1) (2024)
Ginette S Santiago-Sanchez, Kellsye P Fabian, James W Hodge
A landscape of checkpoint blockade resistance in cancer: underlying mechanisms and current strategies to overcome resistance. Cancer biology & therapy 25 (1) (2024)
David Zahavi, James W Hodge
Targeting Immunosuppressive Adenosine Signaling: A Review of Potential Immunotherapy Combination Strategies. International journal of molecular sciences 24 (10) (2023)
S Elizabeth Franks, Ginette S Santiago-Sanchez, Kellsye P Fabian, Kristen Solocinski, Paul L Chariou, Duane H Hamilton, Joshua T Kowalczyk, Michelle R Padget, Sofia R Gameiro, Jeffrey Schlom, James W Hodge
Exploiting docetaxel-induced tumor cell necrosis with tumor targeted delivery of IL-12. Cancer immunology, immunotherapy : CII (2023)
Kellsye P Fabian, Joshua T Kowalczyk, Sandy T Reynolds, James W Hodge
Dying of Stress: Chemotherapy, Radiotherapy, and Small-Molecule Inhibitors in Immunogenic Cell Death and Immunogenic Modulation. Cells 11 (23) (2022)
Kellsye P Fabian, Joshua T Kowalczyk, Sandy T Reynolds, James W Hodge
Dying of Stress: Chemotherapy, Radiotherapy, and Small-Molecule Inhibitors in Immunogenic Cell Death and Immunogenic Modulation. Cells 11 (23) (2022)
S Elizabeth Franks, Kellsye P Fabian, Ginette S Santiago-Sanchez, Benjamin Wolfson, James W Hodge
Immune targeting of three independent suppressive pathways (TIGIT, PD-L1, TGFβ) provides significant antitumor efficacy in immune checkpoint resistant models. Oncoimmunology 11 (1) (2022)
Benjamin Wolfson, Michelle R Padget, Jeffrey Schlom, James W Hodge
Exploiting off-target effects of estrogen deprivation to sensitize estrogen receptor negative breast cancer to immune killing. Journal for immunotherapy of cancer 9 (7) (2022)
Joshua T Kowalczyk, Kellsye P Fabian, Michelle R Padget, Diana C Lopez, Austin Tk Hoke, Clint T Allen, Mario Hermsen, Nyall R London, James W Hodge
Exploiting the immunogenic potential of standard of care radiation or cisplatin therapy in preclinical models of HPV-associated malignancies. Journal for immunotherapy of cancer 10 (12) (2022)
Kellsye P Fabian, Joshua T Kowalczyk, Sandy T Reynolds, James W Hodge
Dying of Stress: Chemotherapy, Radiotherapy, and Small-Molecule Inhibitors in Immunogenic Cell Death and Immunogenic Modulation. Cells 11 (23) (2022)
Joshua T Kowalczyk, Kellsye P Fabian, Michelle R Padget, Diana C Lopez, Austin Tk Hoke, Clint T Allen, Mario Hermsen, Nyall R London, James W Hodge
Exploiting the immunogenic potential of standard of care radiation or cisplatin therapy in preclinical models of HPV-associated malignancies. Journal for immunotherapy of cancer 10 (12) (2022)
Joshua T Kowalczyk, Kellsye P Fabian, Michelle R Padget, Diana C Lopez, Austin Tk Hoke, Clint T Allen, Mario Hermsen, Nyall R London, James W Hodge
Exploiting the immunogenic potential of standard of care radiation or cisplatin therapy in preclinical models of HPV-associated malignancies. Journal for immunotherapy of cancer 10 (12) (2022)
Kellsye P Fabian, Joshua T Kowalczyk, Sandy T Reynolds, James W Hodge
Dying of Stress: Chemotherapy, Radiotherapy, and Small-Molecule Inhibitors in Immunogenic Cell Death and Immunogenic Modulation. Cells 11 (23) (2022)
Benjamin Wolfson, S Elizabeth Franks, James W Hodge
Stay on Target: Reengaging Cancer Vaccines in Combination Immunotherapy. Vaccines 9 (5) (2021)
Kellsye P Fabian, Michelle R Padget, Renee N Donahue, Kristen Solocinski, Yvette Robbins, Clint T Allen, John H Lee, Shahrooz Rabizadeh, Patrick Soon-Shiong, Jeffrey Schlom, James W Hodge
PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations. Journal for immunotherapy of cancer 8 (1) (2021)
Kellsye P Fabian, Michelle R Padget, Rika Fujii, Jeffrey Schlom, James W Hodge
Differential combination immunotherapy requirements for inflamed (warm) tumors versus T cell excluded (cool) tumors: engage, expand, enable, and evolve. Journal for immunotherapy of cancer 9 (2) (2021)
Kristen Solocinski, Michelle R Padget, Kellsye P Fabian, Benjamin Wolfson, Fabiola Cecchi, Todd Hembrough, Stephen C Benz, Shahrooz Rabizadeh, Patrick Soon-Shiong, Jeffrey Schlom, James W Hodge
Overcoming hypoxia-induced functional suppression of NK cells. Journal for immunotherapy of cancer 8 (1) (2021)
Erika J Lampert, Alexandra S Zimmer, Michelle Padget, Ashley Cimino-Mathews, Jayakumar R Nair, Yingmiao Liu, Elizabeth M Swisher, James W Hodge, Andrew B Nixon, Erin Nichols, Mohammad Hadi Bagheri, Elliott Levy, Marc R Radke, Stanley Lipkowitz, Christina M Annunziata, Janis M Taube, Seth M Steinberg, Jung-Min Lee
Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study. Clinical cancer research : an official journal of the American Association for Cancer Research 26 (16) (2020)
S Elizabeth Franks, Benjamin Wolfson, James W Hodge
Natural Born Killers: NK Cells in Cancer Therapy. Cancers 12 (8) (2020)
Kellsye P Fabian, Anthony S Malamas, Michelle R Padget, Kristen Solocinski, Benjamin Wolfson, Rika Fujii, Houssein Abdul Sater, Jeffrey Schlom, James W Hodge
Therapy of Established Tumors with Rationally Designed Multiple Agents Targeting Diverse Immune-Tumor Interactions: Engage, Expand, Enable. Cancer immunology research 9 (2) (2020)
Kristin C Hicks, Karin M Knudson, Karin L Lee, Duane H Hamilton, James W Hodge, William Douglas Figg, Peter Ordentlich, Frank R Jones, Shahrooz Rabizadeh, Patrick Soon-Shiong, Jeffrey Schlom, Sofia R Gameiro
Cooperative Immune-Mediated Mechanisms of the HDAC Inhibitor Entinostat, an IL15 Superagonist, and a Cancer Vaccine Effectively Synergize as a Novel Cancer Therapy. Clinical cancer research : an official journal of the American Association for Cancer Research 26 (3) (2019)
Jay Friedman, Ellen C Moore, Paul Zolkind, Yvette Robbins, Paul E Clavijo, Lilian Sun, Sarah Greene, Megan V Morisada, Wojciech K Mydlarz, Nicole Schmitt, James W Hodge, Hans Schreiber, Carter Van Waes, Ravindra Uppaluri, Clint Allen
Neoadjuvant PD-1 Immune Checkpoint Blockade Reverses Functional Immunodominance among Tumor Antigen-Specific T Cells. Clinical cancer research : an official journal of the American Association for Cancer Research 26 (3) (2019)
Rika Fujii, Caroline Jochems, Sarah R Tritsch, Hing C Wong, Jeffrey Schlom, James W Hodge
An IL-15 superagonist/IL-15Rα fusion complex protects and rescues NK cell-cytotoxic function from TGF-β1-mediated immunosuppression. Cancer immunology, immunotherapy : CII 67 (4) (2018)